LU 35138

Drug Profile

LU 35138

Latest Information Update: 22 Dec 2003

Price : $50

At a glance

  • Originator Lundbeck A/S
  • Class Antipsychotics; Small molecules
  • Mechanism of Action Dopamine D4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Schizophrenia

Most Recent Events

  • 22 Dec 2003 Discontinued - Phase-II for Schizophrenia in Denmark (unspecified route)
  • 19 Sep 2002 Preclinical data have been added to the Psychotic Disorders pharmacodynamics section
  • 15 Aug 2002 Two preclinical studies have been added to the Psychotic Disorders pharmacodynamics section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top